Hizentra 200mg/ml Solution for Subcutaneous Injection
Hizentra 200mg/ml Solution for Subcutaneous Injection, Human Normal Immunoglobulin is indicated for:
Replacement therapy in adults, children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production (see section 4.4),
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated,
- Hypogammaglobulinaemia and recurrent infections in multiple myeloma (MM) patients,
- Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).
Hizentra is available in the following presentations:
- 1g in 5ml vial
- 2g in 10ml vial
- 4g in 20ml vial
Please visit our Privigen page for information on our Solution for Infusion, Human Normal Immunoglobulin.
Hizentra is distributed in Ireland by Fannin Ltd. in partnership with CSL Behring.
Method of Sale: POM
License Number: EU/1/11/687/001, EU/1/11/687/004 & EU/1/11/687/010
MAH Holder: CSL Behring GmbH
For any further information please speak to your local Fannin Representative or for a copy of the SPC please contact our medical information department at email@example.com or via phone on 0868394447.
IE2017/031/00 Date of Preparation: May 2017
ROI orders / enquiries please contact
+353 1 2907000
+353 1 2907111
Pharma orders / enquiries please contact